In the Review article published in the April issue of Nature Reviews Clinical Oncology there were errors in the clinical data presented in Tables 1 and 2. In addition, the primary end point of the adjuvant AVANT and NSABP-C-08 trials should have been disease-free survival (DFS) instead of progression-free survival (PFS). The errors have been corrected for the HTML and PDF versions of the article.
The online version of the original article can be found at 10.1038/nrclinonc.2011.21
About this article
Cite this article
Ebos, J., Kerbel, R. Correction: Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8, 316 (2011). https://doi.org/10.1038/nrclinonc.2011.74
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer
Cancer and Metastasis Reviews (2012)
Cancer Microenvironment (2011)